Literature DB >> 30268858

Effect of occult cancer screening on mortality in patients with unprovoked venous thromboembolism.

Philippe Robin1, Hans Martin Otten2, Aurélien Delluc3, Nick van Es4, Marc Carrier3, Pierre-Yves Salaün5, Grégoire Le Gal6.   

Abstract

INTRODUCTION: Unprovoked venous thromboembolism (VTE) may be the first manifestation of an underlying cancer. We aimed to determine whether extensive screening for occult cancer in patients with unprovoked VTE was effective in reducing overall mortality among VTE patients included in prospective cancer screening studies.
METHODS: This pre-specified analysis of a systematic review and individual patient data meta-analysis included prospective studies comparing extensive screening with limited screening strategies for detection of occult malignant disease in unprovoked VTE patients. Overall mortality was calculated and compared according to the allocated screening strategies.
RESULTS: Among 1830 included patients, occult cancer was detected either at screening or during a 2-year follow-up period in 98 (5.4%, 95% CI 4.4 to 6.5). Twenty-seven out of the 56 patients (48.2%) diagnosed with cancer in the extensive screening group died during follow-up as compared with 23 out of 42 patients (54.8%) in the limited screening group (HR, 0.83; 95% CI, 0.48-1.45). Subgroup analyses according to time of cancer diagnosis (i.e. at screening vs. during follow-up) and according to whether cancer was diagnosed by limited screening or more extensive testing yielded similar results.
CONCLUSION: In this individual patient data meta-analysis of clinical trials on limited vs. extensive screening, extensive screening for occult malignancy in patients with unprovoked VTE was not effective in reducing overall mortality. Diagnosing an occult cancer in unprovoked VTE patients was associated with a poor outcome.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Fluorodeoxyglucose F18; Multidetector computed tomography; Neoplasms; Positron-emission tomography; Screening; Venous thromboembolism

Mesh:

Year:  2018        PMID: 30268858     DOI: 10.1016/j.thromres.2018.09.055

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  4 in total

1.  Cancer Screening in Patients with Unprovoked Thromboembolism: How to do it and Who Benefits?

Authors:  Filipa Ferreira; José Pereira; Ana Lynce; José Nunes Marques; Ana Martins
Journal:  Cureus       Date:  2020-02-10

2.  The Conundrum of Occult Cancer Screening in Venous Thromboembolism: Lessons from the REMOTEV Registry.

Authors:  Elena-Mihaela Cordeanu; Lucas Jambert; Jonathan Tousch; Corina Mirea; Alexandre Delatte; Waël Younes; Bastien Woehl; Claire Harter; Anne-Sophie Frantz; Amer Hamade; Valérie Schini-Kerth; Patrick Ohlmann; Emmanuel Andres; Dominique Stephan
Journal:  Medicina (Kaunas)       Date:  2022-07-09       Impact factor: 2.948

3.  Factor VIII as a potential player in cancer pathophysiology.

Authors:  Gillian E Walker; Simone Merlin; Diego Zanolini; Andrea Vandoni; Alessandro Volpe; Gianluca Gaidano; Guido Valente; Martina Olivero; Antonia Follenzi
Journal:  J Thromb Haemost       Date:  2022-01-11       Impact factor: 16.036

4.  Risk scores for occult cancer in patients with unprovoked venous thromboembolism: Results from an individual patient data meta-analysis.

Authors:  Frits I Mulder; Marc Carrier; Frederiek van Doormaal; Philippe Robin; Hans-Martin Otten; Pierre-Yves Salaun; Harry R Büller; Grégoire Le Gal; Nick van Es
Journal:  J Thromb Haemost       Date:  2020-08-04       Impact factor: 5.824

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.